Results 31 to 40 of about 36,896 (275)
Comparison between “early” or “late” intravitreal injection of dexamethasone implant in branch (BRVO) or central (CRVO) retinal vein occlusion: six months follow-up [PDF]
, 2017 AIM: The aim of this study was to compare early and late injections of intravitreal dexamethasone implant in patients affected by central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO) with a six-months follow-up.
AUTOLITANO, MONICA +6 more
core +1 more source
Q-enhanced fold-and-bond MEMS inductors [PDF]
, 2008 This work presents a novel coil fabrication technology to enhance quality factor (Q factor) of microfabricated inductors for implanted medical wireless sensing and data/power transfer applications.
Chen, Po-Jui +4 more
core +2 more sources
Endocannabinoid metabolism and transport as targets to regulate intraocular pressure
Experimental Eye Research, 2020 Cannabinoids are part of an endogenous signaling system found throughout the body, including the eye. Hepler and Frank showed in the early 1970s that plant cannabinoids can lower intraocular pressure (IOP), an effect since shown to occur via cannabinoid CB1 and GPR18 receptors. Endocannabinoids are synthesized and metabolized enzymatically.
Sally, Miller +8 more
openaire +3 more sources
Widening use of dexamethasone implant for the treatment of macular edema [PDF]
, 2017 Sustained-release intravitreal 0.7 mg dexamethasone (DEX) implant is approved in Europe for the treatment of macular edema related to diabetic retinopathy, branch retinal vein occlusion, central retinal vein occlusion, and non-infectious uveitis.
Avitabile T. +9 more
core +2 more sources
Matrix Metalloproteinases and Glaucoma Treatment. [PDF]
, 2020 Matrix metalloproteinases (MMPs) are a family of proteolytic enzymes that degrade extracellular matrix (ECM) components such as collagen and have important roles in multiple biological processes, including development and tissue remodeling, both in ...
Dibas, Mohammed +3 more
core
Pharmacogenetics of ophthalmic topical β-blockers [PDF]
, 2008 Glaucoma is the second leading cause of blindness worldwide. The primary glaucoma risk factor is elevated intraocular pressure. Topical β-blockers are affordable and widely used to lower intraocular pressure.
McCarty, Catherine A. +4 more
core +1 more source
The Outcomes of Bleb Revision Surgery Techniques After Trabeculectomy
Türk Oftalmoloji Dergisi, 2012 Pur po se: To evaluate the techniques and the results of revision surgeries in order to manage bleb failure after trabeculectomy. Ma te ri al and Met hod: The records of 23 eyes who had undergone bleb revision surgery because of bleb failure after ...
Orhan Ayar +5 more
doaj +1 more source
Therapeutic Advances in Ophthalmology, 2020 Background: Glaucoma is most common irreversible cause of blindness in India. First line management of open-angle glaucoma is either beta blockers or prostaglandin analogs monotherapy.
Alok Dixit, Atul Ashish, Reena Sharma
doaj +1 more source
Target IOP as a measure of glaucoma surgery efficacy
Oftalʹmologiâ, 2015 There are numerous criteria of glaucoma surgery efficacy. Among them, IOP level is of special importance. The development of tolerant and target IOP concepts as well as IOP tolerability issue are reviewed below.
S. Yu. Petrov
doaj +3 more sources
Pro-Secretory Activity and Pharmacology in Rabbits of an Aminophenyl-1,3,5-Triazine CFTR Activator for Dry Eye Disorders. [PDF]
, 2017 PurposePharmacological activation of ocular surface cystic fibrosis transmembrane conductance regulator (CFTR) chloride channels is a potential pro-secretory approach to treat dry eye disorders.
Felix, Christian M +3 more
core +2 more sources